Breakthrough in Breast Cancer Treatment: Novel Synergistic Chemo-Immunotherapy Platform Developed

Strategic Insights -

Research conducted by a team of scientists at Qingdao University has led to the development of a novel synergistic chemo-immunotherapy platform for breast cancer treatment. The study, published in the journal Colloid and Interface Science Communications, aimed to create a nanosystem that could co-encapsulate phloretin (PHL) and Mn2+ ions, utilizing oxidized hyaluronic acid (OHA) modified with lysine (Lys). The anti-tumor efficacy of this platform was evaluated in vitro and in vivo, demonstrating significant tumor inhibition and activation of the cGAS-STING pathway.

Key Takeaways:

  • The novel synergistic chemo-immunotherapy platform, OHA@Lys/PHL Mn2+, achieved 80.3% cell viability inhibition on 4 T-1 breast cancer cells.
  • In combination with cisplatin (CDDP), OHA@Lys/PHL Mn2+ further suppressed proliferation, induced apoptosis, and enhanced ROS accumulation.
  • Mechanistically, the nanosystem induced DNA double-strand damage and activated the cGAS-STING pathway.
  • In vivo, OHA@Lys/PHL Mn2+ monotherapy showed significant tumor inhibition (46.4%).
  • The study concluded that this strategy offers a promising and clinically translatable approach for advanced breast cancer treatment.

Statistics:

  • 80.3% cell viability inhibition achieved by OHA@Lys/PHL Mn2+ on 4 T-1 breast cancer cells.
  • 46.4% tumor inhibition achieved by OHA@Lys/PHL Mn2+ monotherapy in vivo.
  • Combination therapy with CDDP further suppressed proliferation by 25% and induced apoptosis by 35%.

Sources:

  • Newsx. Recent Research from Qingdao University Highlight Findings in Breast Cancer. Immunotherapy Weekly. September 24, 2025; p 549.
  • Colloid and Interface Science Communications. Mn 2+-coordinated Hyaluronic Acid Modified Nanoparticles for Phloretin Delivery: Breast Cancer Treatment, 2025;68.